Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Surv Ophthalmol. 2017 Dec 27;63(4):453–479. doi: 10.1016/j.survophthal.2017.12.008

Figure 20. (A) Treatment with Flt23k nanoparticle plus triamcinolone increased graft survival compared with triamcinolone and triamcinolone plus blank nanoparticles.

Figure 20

(P = 0.048, P = 0.020, respectively). +Sensored data, *P < 0.05, **P < 0.01. (B) The Flt23k nanoparticle plus triamcinolone group showed less total NV compared with the triamcinolone group (P = 0.000) and triamcinolone plus blank nanoparticle group (P = 0.028). The Flt23k nanoparticle plus triamcinolone group showed less graft NV compared with the triamcinolone group (P = 0.008). (C) The Flt23k nanoparticle plus triamcinolone group showed significantly less total lymphangiogenesis compared with the triamcinolone group (P = 0.043) and triamcinolone plus blank nanoparticle group (P = 0.014). The Flt23k nanoparticle plus triamcinolone group showed less graft lymphangiogenesis compared with the triamcinolone plus blank nanoparticle group (P = 0.028). (D) Representative images of NV (upper row) and lymphangiogenesis (lower row) in each group.40 (Adapted from Cho et al with permission from IOVS)